IFNγ responses to pre-erythrocytic and blood-stage malaria antigens exhibit differential associations with past exposure and subsequent protection

Journal of Infectious Diseases

Volumn 211, Issue 12, 2015, Pages 1987-1996

  Jagannathan, Prasanna ^a   Nankya, Felistas ^b   Stoyanov, Cristina ^a   Eccles James, Ijeoma ^a   Sikyomu, Esther ^b   Naluwu, Kate ^b   Wamala, Samuel ^b   Nalubega, Mayimuna ^b   Briggs, Jessica ^a   Bowen, Katherine ^a   Bigira, Victor ^b   Kapisi, James ^b   Kamya, Moses R ^c   Dorsey, Grant ^a   Feeney, Margaret E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

antimalarial chemoprevention; falciparum; IFN ; immunity; malaria; T cell

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DIHYDROARTEMISININ PLUS PIPERAQUINE; ERYTHROCYTE ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; PARASITE ANTIGEN;

AGE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CHILD; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSPOT ASSAY; EXPOSURE; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; UGANDA; CONTROLLED STUDY; FEMALE; IMMUNOLOGY; MALARIA; MALE; PLASMODIUM; PRESCHOOL CHILD; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SECRETION (PROCESS); T LYMPHOCYTE;

ANTIGENS, PROTOZOAN; CHEMOPREVENTION; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; INFANT; INTERFERON-GAMMA; LONGITUDINAL STUDIES; MALARIA; MALE; PLASMODIUM; T-LYMPHOCYTES; UGANDA;

EID: 84930373334     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu814     Document Type: Article

References (50)

1. WHO. World Malaria Report 2013. World Malaria Report 2013 2013:1-284.
2. Jagannathan P, Muhindo MK, Kakuru A, et al. Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, Uganda. Malar J 2012; 11:435.
3. Hoffman SL, Oster CN, Mason C, et al. Human lymphocyte proliferative response to a sporozoite T cell epitope correlates with resistance to falciparum malaria. J Immunol 1989; 142:1299-303.
4. Luty AJ, Lell B, Schmidt-Ott R, et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis 1999; 179:980-8.
5. Kurtis JD, Hollingdale MR, Luty AJ, Lanar DE, Krzych U, Duffy PE. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends Parasitol 2001; 17:219-23.
6. Reece WH, Pinder M, Gothard PK, et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004; 10:406-10.
7. Todryk SM, Bejon P, Mwangi T, et al. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One 2008; 3: e2027.
8. Moormann AM, Sumba PO, Chelimo K, et al. Humoral and Cellular Immunity to Plasmodium falciparum Merozoite Surface Protein 1 and Protection From Infection With Blood-Stage Parasites. J Infect Dis 2013; 208:149-58.
9. Ogutu BR, Apollo OJ, McKinney D, et al. Blood-stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 2009; 4: e4708.
10. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521-32.
11. Agnandji ST, Lell B, Fernandes JF, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284-95.
12. Rts SCTP. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014; 11: e1001685.
13. John CC, Moormann AM, Sumba PO, Ofulla AV, Pregibon DC, Kazura JW. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun 2004; 72:5135-42.
14. Hill AV. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol 2006; 6:21-32.
15. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967; 216:160-2.
16. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973; 266:169-77.
17. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002; 185:1155-64.
18. Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013; 341:1359-65.
19. Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebocontrolled trials. Lancet 2009; 374:1533-42.
20. Wilson AL, Taskforce IP. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One 2011; 6:e16976.
21. Greenwood BM, David PH, Otoo-Forbes LN, et al. Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. Trans R Soc Trop Med Hyg 1995; 89:629-33.
22. Aponte JJ, Menendez C, Schellenberg D, et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med 2007; 4:e242.
23. Belnoue E, Costa FT, Frankenberg T, et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004; 172:2487-95.
24. Putrianti ED, Silvie O, Kordes M, Borrmann S, Matuschewski K. Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites. J Infect Dis 2009; 199: 899-903.
25. Roestenberg M, McCall M, Hopman J, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009; 361:468-77.
26. Roestenberg M, Teirlinck AC, McCall MB, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011; 377:1770-6.
27. Friesen J, Silvie O, Putrianti ED, Hafalla JC, Matuschewski K, Borrmann S. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med 2010; 2:40ra9.
28. Cockburn IA, Chen YC, Overstreet MG, et al. Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog 2010; 6:e1000877.
29. Jagannathan P, Eccles-James I, Bowen K, et al. IFN/IL-10 Co-producing Cells Dominate the CD4 Response to Malaria in Highly Exposed Children. PLoS Pathog 2014; 10:e1003864.
30. Kilama M, Smith DL, Hutchinson R, et al. Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. Malar J 2014; 13:111.
31. Bigira V, Kapisi J, Clark TD, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med 2014; 11:e1001689.
32. Doolan DL, Southwood S, Freilich DA, et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A 2003; 100:9952-7.
33. van Schaijk BC, Janse CJ, van Gemert GJ, et al. Gene disruption of Plasmodium falciparum p52 results in attenuation ofmalaria liver stage development in cultured primary human hepatocytes. PLoS ONE 2008; 3: e3549.
34. Huaman MC, Mullen GE, Long CA, Mahanty S. Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells. Vaccine 2009; 27:5239-46.
35. Makobongo MO, Riding G, Xu H, et al. The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proc Natl Acad Sci U S A 2003; 100:2628-33.
36. Streeck H, Frahm N, Walker BD. The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc 2009; 4:461-9.
37. Lamoreaux L, Roederer M, Koup R. Intracellular cytokine optimization and standard operating procedure. Nat Protoc 2006; 1:1507-16.
38. Ho M, Webster HK, Looareesuwan S, et al. Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. J Infect Dis 1986; 153:763-71.
39. Hviid L, Kurtzhals JA, Goka BQ, Oliver-Commey JO, Nkrumah FK, Theander TG. Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated Plasmodium falciparum malaria. Infect Immun 1997; 65:4090-3.
40. Bejon P, Warimwe G, Mackintosh CL, et al. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun 2009; 77:1917-23.
41. Stowers AW, Chen Lh LH, Zhang Y, et al. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci U S A 2002; 99:339-44.
42. Stowers AW, Cioce V, Shimp RL, et al. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun 2001; 69:1536-46.
43. Chelimo K, Embury PB, Sumba PO, et al. Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein. PLoS One 2011; 6:e24852.
44. O'Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10 Nat Rev Immunol 2007; 7:425-8.
45. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987; 330:664-6.
46. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989; 341:323-6.
47. Schmidt NW, Podyminogin RL, Butler NS, et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci U S A 2008; 105:14017-22.
48. Overstreet MG, Cockburn IA, Chen YC, Zavala F. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunol Rev 2008; 225:272-83.
49. Olotu A, Moris P, Mwacharo J, et al. Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01(E) and Protection against P falciparum Clinical Malaria. PLoS One 2011; 6:e25786.
50. Epstein JE, Tewari K, Lyke KE, et al. Live Attenuated Malaria Vaccine Designed to Protect through Hepatic CD8+ T Cell Immunity. Science 2011; 334:475-80.